AMR SVG Icons location

VasopressinInjection, USP

  • Vial closure is not made with natural rubber latex
  • Formulated, filled, and finished in our US-based manufacturing facilities

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Vial Opening Size Product Info Availability

20 Units/mL

Supplied As:

1 mL
Single Dose Vial

NDC#: 0517-1020-25

20 Units/mL

1 mL
Single Dose Vial

25 13 mm In Stock
  • Shelf Pack 25
  • Availability In Stock

Contains 5 mg chlorobutanol as a preservative

Wholesaler Numbers

  • ABC 10264598
  • Cardinal 1652452
  • McKesson 1613744
  • Morris & Dickson 198762

Case Information

  • Unit of Sale NDC 0517-1020-25
  • Order Size 25
  • Case Size 24
  • Case Per Tier 110

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to

Vasopressin Injection, USP

For intravenous use.


Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.


Vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.

Worsening Cardiac Function – A decrease in cardiac index may be observed with the use of vasopressin.
Reversible Diabetes Insipidus - Patients may experience reversible diabetes insipidus, manifested by the development of polyuria a dilute urine, and hypernatremia after cessation of treatment with vasopressin.

The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure:

Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding
Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia
Gastrointestinal disorders: Mesenteric ischemia
Hepatobiliary: Increased bilirubin levels
Renal/urinary disorders: Acute renal insufficiency
Vascular disorders: Distal limb ischemia
Metabolic: Hyponatremia
Skin: Ischemic lesions

Pressor effects of catecholamines and vasopressin injection are expected to be additive

Indomethacin may prolong effects of vasopressin injection

Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response

Co-administration of drugs causing diabetes insipidus may decrease the pressor response

Pregnancy: May induce tonic uterine contractions.
Pediatric Use: Safety and effectiveness have not been established.
Geriatric Use: Dose selection for an elderly patient should be cautious.

Overdosage with vasopressin injection can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.

Direct effects will resolve within minutes of withdrawal of treatment.

For additional safety information, please see Full Prescribing Information.

You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting or calling 1-800-FDA-1088.